Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats

PLoS One. 2016 Jan 5;11(1):e0145946. doi: 10.1371/journal.pone.0145946. eCollection 2016.

Abstract

We aimed to evaluate macrophages heterogeneity and structural, functional and inflammatory alterations in rat kidney by aldosterone + salt administration. The effects of treatment with spironolactone on above parameters were also analyzed. Male Wistar rats received aldosterone (1 mgkg-1d-1) + 1% NaCl for 3 weeks. Half of the animals were treated with spironolactone (200 mg kg-1d-1). Systolic and diastolic blood pressures were elevated (p<0.05) in aldosterone + salt-treated rats. Relative kidney weight, collagen content, fibronectin, macrophage infiltrate, CTGF, Col I, MMP2, TNF-α, CD68, Arg2, and SGK-1 were increased (p<0.05) in aldosterone + salt-treated rats, being reduced by spironolactone (p<0.05). Increased iNOS and IFN-γ mRNA gene expression (M1 macrophage markers) was observed in aldosterone + salt rats, whereas no significant differences were observed in IL-10 and gene ArgI mRNA expression or ED2 protein content (M2 macrophage markers). All the observed changes were blocked with spironolactone treatment. Macrophage depletion with liposomal clodronate reduced macrophage influx and inflammatory M1 markers (INF-γ or iNOS), whereas interstitial fibrosis was only partially reduced after this intervention, in aldosterone plus salt-treated rats. In conclusion, aldosterone + salt administration mediates inflammatory M1 macrophage phenotype and increased fibrosis throughout mineralocorticoid receptors activation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aldosterone / administration & dosage
  • Aldosterone / immunology*
  • Animals
  • Fibrosis
  • Inflammation / drug therapy
  • Inflammation / immunology
  • Inflammation / pathology*
  • Kidney / drug effects
  • Kidney / immunology
  • Kidney / pathology*
  • Kidney Diseases / drug therapy
  • Kidney Diseases / immunology
  • Kidney Diseases / pathology*
  • Macrophages / immunology
  • Macrophages / pathology*
  • Male
  • Mineralocorticoid Receptor Antagonists / pharmacology
  • Rats
  • Rats, Wistar
  • Receptors, Mineralocorticoid / immunology*
  • Sodium Chloride / administration & dosage
  • Sodium Chloride / immunology*
  • Spironolactone / pharmacology

Substances

  • Mineralocorticoid Receptor Antagonists
  • Receptors, Mineralocorticoid
  • Spironolactone
  • Sodium Chloride
  • Aldosterone

Grants and funding

This work has been supported by grants from Fondo de Investigaciones Sanitaria (FIS, Programa Miguel Servet: CP10/00479, PI13/00802 and PI14/00883), Spanish Society of Nephrology to Juan Antonio Moreno, Fundación Conchita Rabago to Alfonso Rubio-Navarro, Institute of Research Queen Sophia, Fundacion Renal Iñigo Alvarez de Toledo (FRIAT) and Instituto de Salud Carlos III (ISCIII) fund PI14/00386 to Jesús Egido and VI Programa Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica de España (SAF2011-30396). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.